STAT3 and renal carcinoma: Their ability to modulate the inactivated Hippo pathway in mesothelioma, as well as inhibit AKT/mTOR, ERK and JAK/STAT3 pathways in renal cancer cells in vitro [32,49] supported Meta-Analyses based studies showing a beneficial effect of statins for both overall survival and cancer-specific survival [50,51].